GleamWall
中文EN

BEAT HeartBeam, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1779372 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY12.5%
TTM EPS YoY40.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-521.7%
ROA-335.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets17.3%
Debt / equity0.00x
Current ratio4.64x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.69x
Accruals ratio-104.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$2.12M$2.33M$2.37M$3.35M$3.28M$3.33M$3.49M$2.89M
SG&A expense$1.34M$2.76M$2.35M$1.96M$2.01M$1.71M$2.01M$2.06M
Operating income-$3.46M-$5.09M-$4.72M-$5.31M-$5.29M-$5.04M-$5.50M-$4.94M
Pretax income-$3.01M-$5.04M-$4.70M-$5.30M-$5.25M-$4.97M-$5.48M-$4.91M
Income tax$0$0$0$0$0$0$0$0
Net income-$3.01M-$5.04M-$4.70M-$5.30M-$5.25M-$4.97M-$5.48M-$4.91M
EBITDA-$3.39M-$5.04M-$4.69M-$5.29M-$5.28M-$5.03M-$5.50M-$4.94M
EPS (basic)-0.05-0.10-0.12—-0.15-0.15-0.18—
EPS (diluted)-0.05-0.10-0.12—-0.15-0.15-0.18—
Weighted avg. shares (diluted)57.20M52.77M40.59M—34.40M33.83M30.38M—
Balance sheet
Cash & equivalents$6.07M$8.72M$2.04M$4.38M$1.86M$3.26M$4.39M$2.43M
Inventory$114,000$110,000$133,000$103,000———$0
Current assets$6.30M$9.00M$2.44M$4.68M$2.13M$5.36M$8.61M$2.77M
PP&E, net$1.52M$1.58M$1.44M$1.10M$694,000$564,000$443,000$450,000
Total assets$7.87M$10.64M$3.93M$5.84M$2.88M$5.98M$9.11M$3.28M
Current liabilities$1.36M$2.46M$3.29M$3.24M$2.47M$1.80M$1.58M$1.62M
Total liabilities$1.36M$2.46M$3.29M$3.24M$2.47M$1.80M$1.58M$1.62M
Shareholders' equity$6.51M$8.18M$635,000$2.60M$406,000$4.18M$7.53M$1.65M
Shares outstanding57.51M56.35M41.13M40.12M34.34M34.02M33.73M26.96M
Cash flow statement
Operating cash flow-$2.59M-$3.34M-$3.61M-$2.91M-$3.16M-$3.44M-$4.48M-$4.15M
Capital expenditure$69,000$249,000$246,000$416,000$82,000$102,000$0$0
Free cash flow-$2.66M-$3.59M-$3.86M-$3.32M-$3.24M-$3.55M-$4.48M-$4.15M
Investing cash flow-$69,000-$249,000-$246,000-$416,000$1.72M$1.86M-$3.76M$0
Financing cash flow$0$10.28M$1.51M$5.85M$45,000$450,000$10.25M$761,000
Depreciation & amortization$69,000$57,000$24,000$17,000$8,000$8,000$7,000$7,000
Stock-based compensation$937.00M$1.70B$1.22M$1.43M$1.43B$1.18B$1.11M$999,000

Free plan shows the latest 8 periods; Pro shows all 25 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.